Skip to main content
Journal cover image

Mavacamten for hypertrophic obstructive cardiomyopathy.

Publication ,  Journal Article
Quintana, E; Bajona, P; Myers, PO
Published in: Lancet
January 30, 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

January 30, 2021

Volume

397

Issue

10272

Start / End Page

369

Location

England

Related Subject Headings

  • Uracil
  • Humans
  • General & Internal Medicine
  • Double-Blind Method
  • Cardiomyopathy, Hypertrophic
  • Benzylamines
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Quintana, E., Bajona, P., & Myers, P. O. (2021). Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet, 397(10272), 369. https://doi.org/10.1016/S0140-6736(20)32384-9
Quintana, Eduard, Pietro Bajona, and Patrick O. Myers. “Mavacamten for hypertrophic obstructive cardiomyopathy.Lancet 397, no. 10272 (January 30, 2021): 369. https://doi.org/10.1016/S0140-6736(20)32384-9.
Quintana E, Bajona P, Myers PO. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021 Jan 30;397(10272):369.
Quintana, Eduard, et al. “Mavacamten for hypertrophic obstructive cardiomyopathy.Lancet, vol. 397, no. 10272, Jan. 2021, p. 369. Pubmed, doi:10.1016/S0140-6736(20)32384-9.
Quintana E, Bajona P, Myers PO. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021 Jan 30;397(10272):369.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

January 30, 2021

Volume

397

Issue

10272

Start / End Page

369

Location

England

Related Subject Headings

  • Uracil
  • Humans
  • General & Internal Medicine
  • Double-Blind Method
  • Cardiomyopathy, Hypertrophic
  • Benzylamines
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences